Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001213900-15-007437
Filing Date
2015-10-02
Accepted
2015-10-02 16:25:56
Documents
10

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT fs32015_relmadathera.htm S-3 612966
2 CONTROLLED EQUITY OFFERING SALES AGREEMENTSM, DATED OCTOBER 2, 2015, BY AND BETW fs32015ex1ii_relmadathera.htm EX-1.2 280562
3 FORM OF COMMON STOCK CERTIFICATE fs32015ex4i_relmadatherape.htm EX-4.1 978
4 OPINION OF FENNEMORE CRAIG, P.C. fs32015ex5i_relmadathera.htm EX-5.1 28909
5 STATEMENT REGARDING THE COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES fs32015ex12i_relmadatherape.htm EX-12.1 10034
6 CONSENT OF GBH CPAS, PC fs32015ex23i_relmadatherape.htm EX-23.1 1313
7 GRAPHIC image_001.jpg GRAPHIC 41457
8 GRAPHIC img_005.jpg GRAPHIC 22350
9 GRAPHIC ex4i_1.jpg GRAPHIC 156991
10 GRAPHIC ex4i_2.jpg GRAPHIC 146197
  Complete submission text file 0001213900-15-007437.txt   1441748
Mailing Address 546 FIFTH AVENUE, 14TH FLOOR NEW YORK NY 10036
Business Address 546 FIFTH AVENUE, 14TH FLOOR NEW YORK NY 10036 212-702-7163
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 0630
Type: S-3 | Act: 33 | File No.: 333-207248 | Film No.: 151140690
SIC: 2834 Pharmaceutical Preparations